Sean Jeong, also known as Seungwon, M.D., MBA, serves as President & Director at Hanall Biopharma Co.,Ltd since 2021 and is its Co-Chief Executive Officer since April 2023 and was its Chief Executive Offic...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sean Jeong	President	3.4yrs	데이터 없음	데이터 없음
Su-Jin Park	Co-CEO, VP & Director	1.2yrs	데이터 없음	0.00059% ₩ 9.3m
Sung-Hou Kim	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Seung-Kook Park	Director	no data	데이터 없음	0.14% ₩ 2.2b
Jae-Ho Cheong	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yong Choi	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Aekyung Kim	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Young Shin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jason Song	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jae-chun Yoon	Chairman	no data	데이터 없음	데이터 없음
Hun Jung	Independent Director	3.4yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

경험이 풍부한 이사회: A009420 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Hanall Biopharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Recent updates

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

CEO

테뉴어

이사회 구성원

평균 재임 기간